Medical device regulatory developments from the US and Thailand include: final FDA guidance on modular review for premarket approval applications and humanitarian device exemptions, and new expedited regulatory routes for low-risk devices and chronic disease prevention devices in Thailand.
The FDA has issued its final guidance on the modular review process for Premarket Approval Applications (PMA) and Humanitarian Device Exemptions (HDE), effective January 2025. This guidance provides detailed procedures for the submission and review of modular PMAs and HDEs, streamlining the process for industry stakeholders. Issued by the Center for Devices and Radiological Health and the Center for Biologics Evaluation and Research, the document is associated with Docket Number FDA-2024-D-5332. Public comments are welcomed and can be submitted online or in writing at any time.
Learn more about FDA US Medical Device Registration.
Starting January 15, 2025, the Thai FDA will implement an automated approval system for Class 1 low-risk medical devices. This system, known as the "Positive List," is designed to significantly reduce the time required to approve low-risk devices, facilitating faster market access for entrepreneurs.
The initiative ensures that users gain quicker access to vital medical devices while simplifying the approval process for businesses. Entrepreneurs and stakeholders can access further details through the links below:
On January 22, 2025, the Thai FDA announced a priority track for the registration and import of medical devices aimed at preventing and managing chronic diseases such as diabetes, hypertension, high cholesterol, cardiovascular diseases, and cancer.
Medical devices eligible for this fast-track process include:
This initiative underscores the FDA’s commitment to combating the growing prevalence of chronic diseases in Thailand. For more information on the priority track, visit the official announcement.
Learn more about TFDA Thailand Medical Device Registration.
Browse our news hub featuring company announcements, regulatory updates, and industry insights to keep you informed and ahead of the curve.
Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.
Explore our collection of articles, success stories, and regulatory updates, designed to help you take your product global.
The IVDR transition includes structured processes IVD manufacturers must follow to engage with Notified Bodies. Many IVD manufacturers are interacting with Notified Bodies for the first time and must understand what is required to ensure a successful partnership. In this article, Dr. Oliver Eikenberg clarifies what manufacturers must prepare and when to engage a Notified Body for IVDR CE Marking.
Class D IVD manufacturers face fast-approaching IVDR transition deadlines, though some are more familiar with the regulatory process. In this article, Dr. Oliver Eikenberg discusses the difference between "new" and "old" Class Ds, and regulatory logistics they need to consider during the transition process.
Your IVD's intended purpose determines its classification, clinical evidence requirements, and clinical applications under the IVDR. Device companies will need a more robust intended purpose to fulfill IVDR criteria. In this article, Dr. Oliver Eikenberg explains the role of the intended purpose in IVDR compliance.
